Marker Therapeutics logo
Marker Therapeutics MRKR
$ 1.35 0.75%

Annual report 2025
added 03-18-2026

report update icon

Marker Therapeutics Financial Statements 2011-2026 | MRKR

Annual Financial Statements Marker Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

20.5 M 11 M 10.8 M 16.1 M 7.27 M 90 M 122 M 106 M 35.1 M 28.9 M 25.9 M 2.78 M 2.27 M 10.5 M 7.36 M

Shares

15.3 M 8.98 M 8.81 M 8.35 M 7.65 M 46.9 M 45.6 M 19.1 M 9.45 M 6.89 M 3.66 M 1.29 M 94.7 K 54.6 K 38.3 K

Historical Prices

1.34 1.23 1.23 1.93 0.95 1.45 2.88 5.55 3.92 3.88 7.2 3.36 24 144 180

Net Income

-12.2 M -10.7 M -8.24 M -29.9 M -41.9 M -28.7 M -21.4 M -148 M -11 M -2.46 M -34.1 M -30.9 M -5.53 M -5.86 M -2.03 M

Revenue

3.55 M 6.59 M 3.31 M 9.01 M 1.24 M 467 K 213 K 206 K - - - - - - -

Gross Profit

- - - - - 467 - - - - - - - - -

Operating Income

-12.9 M -11.1 M -14.6 M -29.9 M -39.5 M -28.9 M -22.5 M -148 M -11.5 M -8.49 M -6.16 M -3.37 M -2.66 M - -3.32 M

EBITDA

-12.9 M -11.1 M -14.6 M -27.2 M -37.3 M -27.8 M -22.2 M -148 M -12 M -8.26 M -6.16 M -3.37 M -2.66 M -5.58 M -2.64 M

Operating Expenses

16.4 M 17.7 M 17.9 M 39 M 40.7 M 29.4 M 22.7 M 148 M 11.5 M 8.26 M 6.16 M 3.37 M 2.66 M 5.48 M 2.64 M

General and Administrative Expenses

4.18 M 4.24 M 7.48 M 12.8 M 12.9 M 10.5 M 9.98 M 24.4 M 6.41 M 4.69 M 4.45 M 3.18 M 2 M 4.42 M 2.43 M

All numbers in USD currency

Quarterly Income Statement Marker Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

16.8 M 14 M 11.1 M 10.7 M 8.92 M 8.92 M 8.9 M 8.9 M 8.83 M 8.8 M 8.72 M 8.4 M 8.36 M 8.36 M 8.31 M 83.1 M 83.1 M 83 M 56.5 M 50.7 M 46.9 M 46.6 M 46.1 M 45.7 M 45.7 M 45.5 M 45.5 M 45.4 M 13.7 M 11.8 M 10.6 M 10.6 M 10.2 M 8.58 M 8.43 M 8.4 M 7.28 M 5.94 M 5.88 M 5.88 M 4.05 M 33.5 M 27.6 M 20.3 M 17.3 M 15.5 M 7.63 M 1.47 M 1.27 M 1 M 807 K 764 K 76.4 M 62 M 52.5 M 52.1 M 52.1 M 46.7 M 52.1 M

Net Income

-2 M -4.02 M -4.45 M - -2.31 M -2.19 M -2.39 M - -2.98 M 2.52 M -4.97 M - -6.92 M -9.24 M -9.91 M - -12.4 M -10.9 M -8.78 M - -7.37 M -6.34 M -6.49 M - -5.46 M -5.57 M -5.32 M - -4.39 M -4.81 M -3.2 M - -3.99 M -1.89 M -2.42 M - -2.1 M 5.97 M -4.75 M - 28.5 M -60.2 M -701 K - -1.57 M 753 K -29.7 M - -2.06 M -871 K -85.1 M - - -2.54 M -599 K - -844 K -404 K -1.27 M

Revenue

1.23 M 861 K 349 K - 1.93 M 1.17 M 1.24 M - 258 K 763 K 1.23 M - 1 M 791 K 964 K - - - - - - 467 K - - - - - - - 206 K - - 183 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-2.14 M -4.26 M -4.61 M - -2.4 M -2.31 M -2.55 M - -3.2 M -4.13 M -4.31 M - -5.83 M -5.27 M -9.79 M - -10 M -10.9 M -8.78 M - -7.38 M -6.36 M -6.64 M - -5.65 M -5.87 M -5.64 M - -4.43 M -4.67 M -3.2 M - -3.99 M -2.39 M -2.42 M - -2.72 M -2.43 M -1.75 M - -1.74 M -1.14 M -1.03 M - - - - - -313 K -675 K -1.12 M - -797 K -3.14 M -672 K - -905 K -701 K -1.1 M

EBITDA

- - - - - - - - - - -3.49 M - -3.85 M -4.11 M -9.22 M - -8.44 M -9.88 M -8.28 M - -7.1 M -6.23 M -6.61 M - -5.58 M -5.83 M -5.63 M - -4.43 M -4.67 M -3.2 M - -3.99 M -2.39 M -2.42 M - -2.72 M -2.43 M -1.75 M - -1.74 M -1.14 M -1.03 M - - - - - -313 K -675 K -902 K - -797 K -3.14 M -672 K - -905 K -701 K -1.1 M

Operating Expenses

3.37 M 5.12 M 4.96 M - 4.33 M 3.48 M 3.79 M - 3.46 M 4.9 M 5.54 M - 6.83 M 6.06 M 10.8 M - 10 M 10.9 M 8.78 M - 7.38 M 6.82 M 6.64 M - 5.65 M 5.87 M 5.64 M - 4.43 M 4.88 M 3.2 M - 4.17 M 2.39 M 2.42 M - 2.72 M 2.43 M 1.75 M - 1.74 M - - - 1.38 M - - - - - - - - - - - - - -

General and Administrative Expenses

1.02 M 945 K 1.37 M - 855 K 1.14 M 1.22 M - 1.41 M 2.52 M 2.17 M - 3.23 M 3.14 M 3.73 M - 3.24 M 3.56 M 3.14 M - 2.57 M 2.55 M 2.83 M - 2.54 M 2.72 M 2.81 M - 2.55 M 3.05 M 1.6 M - 2.55 M 1.19 M 1.43 M - 1.61 M 1.18 M 768 K - 769 K 937 K 419 K - 1.35 M 488 K 1.16 M - 70.5 K 88.1 K 4.7 M - 268 K 468 K 142 K - 23.9 K 37 K 5.12 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Marker Therapeutics MRKR
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Marker Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.67 -0.07 % $ 6.09 B irlandaIrlanda
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cabaletta Bio Cabaletta Bio
CABA
$ 2.82 1.44 % $ 283 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.29 -3.01 % $ 329 M britainBritain
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 3.47 -1.7 % $ 221 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.74 -12.17 % $ 3.25 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.09 -9.17 % $ 22.4 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 2.06 - $ 118 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.85 3.26 % $ 592 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.45 -1.64 % $ 631 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 1.32 -5.2 % $ 1.88 M chinaChina
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.55 0.98 % $ 4.28 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.45 -1.77 % $ 853 M canadaCanada
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA